$0.16
(Market cap
$8 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-7 Mln
-
ROE
-23.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-3.8
-
Face value
--
-
Shares outstanding
30,442,139
10 Years Aggregate
CFO
$-126.71 Mln
EBITDA
$-148.92 Mln
Net Profit
$-156.90 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
AIM ImmunoTech (AIM)
| -- | -- | -- | -- | -28.0 | -34.2 | -44.3 |
|
BSE Sensex*
| -8.9 | 0.4 | 1.6 | -4.5 | 5.9 | 6.6 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
AIM ImmunoTech (AIM)
| -54.7 | 41.9 | -66.3 | -48.6 | 229.0 | -93.2 | -47.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
AIM ImmunoTech (AIM)
|
0.3 | 7.7 | 0.1 | -14.3 | -13,823.2 | -- | -- | 0.9 |
| 88.6 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 249.4 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 77.9 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 55.3 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 106.9 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 543.7 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 611.6 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 367.9 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 149.5 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout AIM ImmunoTech (AIM)
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are... Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida. Read more
-
Executive Vice Chairman, CEO & President
Mr. Thomas K. Equels Esq., J.D., M.S.
-
Executive Vice Chairman, CEO & President
Mr. Thomas K. Equels Esq., J.D., M.S.
-
Headquarters
Ocala, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for AIM ImmunoTech (AIM)
What is the current share price of AIM ImmunoTech Inc (AIM) Today?
The share price of AIM ImmunoTech Inc (AIM) is $0.25 (NYSE) as of 27-Aug-2026 16:10 EDT. AIM ImmunoTech Inc (AIM) has given a return of -28.01% in the last 3 years.
What is the current PB & PE ratio of AIM ImmunoTech Inc (AIM)?
Since, TTM earnings of AIM ImmunoTech Inc (AIM) is negative, P/E ratio is not available.
The P/B ratio of AIM ImmunoTech Inc (AIM) is 0.94 times as on 21-Aug-2026, a 82 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-- |
-- |
2024 |
-0.02 |
-0.23 |
2024 |
-- |
-- |
2023 |
-0.75 |
2.11 |
2023 |
-- |
-- |
What is the 52 Week High and Low of AIM ImmunoTech Inc (AIM)?
The 52-week high and low of AIM ImmunoTech Inc (AIM) are Rs 0.26 and Rs 0.25 as of 28-Aug-2026.
What is the market cap of AIM ImmunoTech Inc (AIM)?
AIM ImmunoTech Inc (AIM) has a market capitalisation of $ 8 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in AIM ImmunoTech Inc (AIM)?
Before investing in AIM ImmunoTech Inc (AIM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.